← back to search

Fidelma Dunne

Ollscoil na Gaillimhe – University of Galway · IE
Area of research
Obstetrics and Gynecology · Surgery
Research interest
Research interests include Gestational Diabetes Research and Management, Pregnancy and preeclampsia studies, Bariatric Surgery and Outcomes, and Birth, Development, and Health.
h-index
54
citations
10,228
works
279
NIH funding
primary concept
Medicine
email

Recent publications

Metformin safety during pregnancy in women with gestational diabetes mellitus: A systematic review and meta-analysis of maternal, neonatal and long-term outcomes.
2026cited by 1position: contributordoi
Prediction of time to insulin initiation in gestational diabetes mellitus: a secondary analysis of the EMERGE trial.
2026cited by 0position: contributordoi
Postnatal Cardiometabolic Health After Metformin Use in Gestational Diabetes: A Secondary Analysis of the EMERGE Trial.
2025cited by 2position: contributordoi
The cardio-metabolic protein profile is associated with development of type 2 diabetes at long term follow-up after gestational diabetes mellitus: Results from the OGFUS study.
2025cited by 2position: contributordoi
ATLANTIC DIP, Changing the Landscape for Better Maternal and Infant Health: The 2024 Norbert Freinkel Award Lecture.
2025cited by 1position: contributordoi
Cost effectiveness of early metformin in addition to usual care in the reduction of gestational diabetes mellitus effects (EMERGE)-A randomised placebo-controlled clinical trial.
2025cited by 1position: contributordoi
Low prolactin levels as a marker of gestational diabetes in late pregnancy.
2025cited by 0position: contributordoi
Rethinking Postpartum Glucose Assessment: Is One-Hour Testing the Key to Success?
2025cited by 0position: contributordoi
Navigating Complexities In Randomized Trials: Insights From The EMERGE Trial Amidst Pandemic And Cybersecurity Threat.
2025cited by 0position: contributordoi
What is the carbon footprint of academic clinical trials? A study of hotspots in 10 trials.
2024cited by 12position: contributordoi
Metformin and small for gestational age babies: findings of a randomised placebo-controlled clinical trial of metformin in gestational diabetes (EMERGE).
2024cited by 6position: contributordoi
Placental structural adaptation to maternal physical activity and sedentary behavior: findings of the DALI lifestyle study.
2024cited by 6position: contributordoi
Treatment of Diabetes in Pregnancy With Metformin.
2024cited by 3position: contributordoi
The top 10 priorities in adults living with type 1 diabetes in Ireland and the United Kingdom - A James Lind Alliance priority setting partnership.
2024cited by 3position: contributordoi
The IRELAnD study-investigating the role of early low-dose aspirin in diabetes mellitus: a double-blinded, placebo-controlled, randomized trial.
2024cited by 3position: contributordoi
Abnormal Glucose Tolerance in Women Diagnosed With Gestational Diabetes (WHO 2013) 10 Years After Index Pregnancy.
2024cited by 2position: contributordoi
Maintaining glucose integrity ex-vivo: Impact of preanalytical specimen handling.
2024cited by 2position: contributordoi
Quantifying the carbon footprint of academic clinical trials: building the evidence base and hotspot identification
2024cited by 1position: contributordoi
A comparison of the safety and effectiveness of insulin aspart with other bolus insulins in women with pre-existing Type 1 diabetes during pregnancy: A post hoc analysis of a prospective cohort study.
2024cited by 0position: contributordoi
Early Metformin Treatment for Gestational Diabetes-Reply.
2024cited by 0position: contributordoi
Early Metformin in Gestational Diabetes: A Randomized Clinical Trial.
2023cited by 66position: contributordoi
Insulin degludec versus insulin detemir, both in combination with insulin aspart, in the treatment of pregnant women with type 1 diabetes (EXPECT): an open‑label, multinational, randomised, controlled, non-inferiority trial.
2023cited by 32position: contributordoi
Attendance at pre-pregnancy care clinics for women with type 1 diabetes: A scoping review.
2023cited by 10position: contributordoi
Focus on Metformin: Its Role and Safety in Pregnancy and Beyond.
2023cited by 9position: contributordoi
Physical activity and sedentary time across pregnancy and associations with neonatal weight, adiposity and cord blood parameters: a secondary analysis of the DALI study.
2023cited by 5position: contributordoi
The ability of pGCD59 to predict adverse pregnancy outcomes: a prospective study of non-diabetic pregnant women in Ireland.
2023cited by 3position: contributordoi
The utility of plasma glycated CD59 in predicting postpartum glucose intolerance: A prospective study of women diagnosed with GDM during a period of universal GDM screening
Diabetic Medicine 2023cited by 2position: lastdoi
The utility of plasma glycated CD59 in predicting postpartum glucose intolerance: A prospective study of women diagnosed with GDM during a period of universal GDM screening.
2023cited by 2position: contributordoi
Metformin for pregnancy and beyond: the pros and cons.
2022cited by 29position: contributordoi
Vitamin D3 Supplementation in Overweight/Obese Pregnant Women: No Effects on the Maternal or Fetal Lipid Profile and Body Fat Distribution—A Secondary Analysis of the Multicentric, Randomized, Controlled Vitamin D and Lifestyle for Gestational Diabetes Prevention Trial (DALI)
Nutrients 2022cited by 22position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

David Simmons · Western Sydney University29 papers (2013–2024)Gernot Desoyé · Camden and Campbelltown Hospitals25 papers (2013–2024)Frank J. Snoek · Amsterdam Neuroscience25 papers (2013–2022)Jürgen Harreiter · Novartis (France)19 papers (2019–2024) · 18 papers (2020–2026)Rosa Corcoy · Hospital de Sant Pau18 papers (2013–2022)Peter Damm · University College Copenhagen13 papers (2013–2022)Roland Devlieger · Universitair Ziekenhuis Leuven13 papers (2013–2022)Mireille N. M. van Poppel · University of Graz10 papers (2013–2022)Annunziata Lapolla · University of Padua10 papers (2013–2022)Elisabeth R. Mathiesen · Novo Nordisk (United States)10 papers (2013–2022)Agnieszka Zawiejska · University of Edinburgh10 papers (2013–2022) · 10 papers (2013–2022)Alexandra Kautzky‐Willer · Vienna General Hospital10 papers (2013–2022) · 9 papers (2013–2022)André Van Assche · KU Leuven9 papers (2013–2018)Andrew Smyth · Trials Methodology Research Network9 papers (2021–2026)Sander Galjaard · KU Leuven9 papers (2013–2022) · 9 papers (2013–2022)Jürgen Harreiter · Australian National University9 papers (2013–2022)